Navigation Links
Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
Date:7/13/2010

CHARLOTTESVILLE, Virginia, July 13, 2010 /PRNewswire/ -- Biovista announced today the appointment of Mr. Clifford H. Farrah, President and Chairman of The Beacon Group, to its Advisory Board.

"We are very excited to have Cliff join our Advisory Board," said Aris Persidis, President of Biovista. "Cliff brings a wealth of direct commercial development experience in the healthcare and biotech market that will be invaluable to us as we grow Biovista," he added.

"Biovista is a new generation biotechnology company with unique technology and capabilities," said Mr. Farrah. "It's rare that you get the opportunity to help a company lead in the new order of drug discovery and development. Biovista is offering a disruptive, rigorous and efficient approach to a costly process, and I am excited to participate in its future."

About the Beacon Group (http://www.tbg-online.com):

The Beacon Group is a strategy consulting firm providing guidance to organizations on their most critical business issues. With a clear focus on achieving top-line growth through both organic and inorganic means, Beacon's output is designed to have a direct impact on client profitability. Healthcare practice base includes Fortune 100 biotech, pharmaceutical, medical device and diagnostics companies.

About Biovista (http://www.biovista.com):

Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own pipeline of drugs in multiple sclerosis, epilepsy, specific cancers and auto-immune diseases. Also, Biovista is collaborating with the FDA on prediction of adverse events, and with biopharmaceutical companies on indication expansion and de-risking of their portfolios.

    For further information please contact:

    Dr. Aris Persidis
    Biovista, Inc.
    arisp@biovista.com
    +1-434-242-6514



'/>"/>
SOURCE Biovista
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
2. Biovista Inc. Named Top Innovator in Life Sciences
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 --> ... "Fetal (Labor & Delivery) and Neonatal Care Equipment Market ... Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - ... studies the global market over the forecast period of ... 6.28 Billion in 2015 and is poised to grow ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last week, ... of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA since ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ) ... event in New York City on Thursday, January 21, 2016. Kingsley R. ... (both alumnus of the varsity Columbia soccer program) spoke at the event, offering ...
(Date:2/4/2016)... ... February 04, 2016 , ... According to a recent ... see their dentist once every six months for a cleaning and checkup, depending on ... Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental Care, notes ...
Breaking Medicine News(10 mins):